{
  "source_pdf": "data/clinical_files/FlublokPI.pdf",
  "blocks": [
    {
      "id": "3f54d4c6",
      "page_index": 0,
      "role": "List",
      "bbox": [
        1748.02099609375,
        2689.1328125,
        3201.100830078125,
        4185.26806640625
      ],
      "text": "• If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior\ninﬂuenza vaccine, the decision to give Flublok should be based on careful\nconsideration of potential beneﬁts and risks. (5.2)\n————————————\nADVERSE REACTIONS\n————————————\n• In adults 18 through 49 years of age, the most common (≥10%) injection-site\nadverse reaction was pain (37%); the most common (≥10%) solicited systemic\nadverse reactions were headache (15%), fatigue (15%) and muscle pain (11%).\n(6.1)\n• In adults 50 through 64 years of age, the most common (≥10%) injection site\nadverse reaction was pain (32%); the most common (≥10%) solicited systemic\nadverse reactions were headache (17%), fatigue (13%), and muscle pain (11%).\n(6.1)\n• In adults 65 years of age and older, the most common (≥10%) injection site\nadverse reaction was pain (19%); the most common (≥10%) solicited systemic\nadverse reactions were fatigue (13%) and headache (10%). (6.1)\nTo report SUSPECTED ADVERSE REACTIONS, contact SanoﬁPasteur Inc., at\n(1-800-822-2463\n(1-800-Vaccine)\nor\nVAERS\nat\n1-800-822-7967\nor\nwww.vaers.hhs.gov.\nSee 17 for PATIENT COUNSELING INFORMATION\nRevised: 07/2024\n8\nUSE IN SPECIFIC POPULATIONS\n8.1\nPregnancy\n8.2\nLactation\n8.4\nPediatric Use",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9620653986930847,
        "detection_dpi": 400
      }
    },
    {
      "id": "772dce4f",
      "page_index": 0,
      "role": "Table",
      "bbox": [
        235.19044494628906,
        1334.8431396484375,
        3136.4541015625,
        2619.71533203125
      ],
      "text": "[TABLE 4 - See table_p1_772dce4f.png]",
      "html": null,
      "image_path": "figures/table_p1_772dce4f.png",
      "metadata": {
        "score": 0.7849844694137573,
        "detection_dpi": 400
      }
    },
    {
      "id": "018f3eb5",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        221.8677520751953,
        3910.20703125,
        1641.9385986328125,
        4183.34130859375
      ],
      "text": "HIGHLIGHTS OF PRESCRIBING INFORMATION\nThesehighlightsdonot includeall theinformationneededtouseFlublok®safely\nand effectively. See full prescribing information for Flublok.\nFlublok (Inﬂuenza Vaccine)\nnjection for Intramuscular Use 2024-2025 Formula",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9709327220916748,
        "detection_dpi": 400
      }
    },
    {
      "id": "5944136b",
      "page_index": 0,
      "role": "List",
      "bbox": [
        1837.7073974609375,
        486.98468017578125,
        3190.822265625,
        1000.0700073242188
      ],
      "text": "ults 65 years of age and older, the most common (≥10%) injection site adverse\non was pain (19%); the most common (≥10%) solicited systemic adverse reactions\nfatigue (13%) and headache (10%). (6.1)\nClinical Trials Experience\nuse clinical studies are conducted under widely varying conditions, adverse reaction\nobserved in the clinical studies of a vaccine cannot be directly compared to rates\ne clinical studies of another vaccine and may not reﬂect the rates observed in clinica\nce.\nsafety experience with Flublok Quadrivalent is relevant to Flublok because both\nnes are manufactured using the same process and have overlapping compositions.\nok\nok has been administered to and safety data collected from2497 adults 18 through",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9319884181022644,
        "detection_dpi": 400
      }
    },
    {
      "id": "cd091c03",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        197.39044189453125,
        3545.83544921875,
        1652.3184814453125,
        3665.6484375
      ],
      "text": "vaccine. Flublok is approved for use in persons 18 years of age and older. (1)\n——————————\nDOSAGE AND ADMINISTRATION\n——————————\nFor intramuscular use (05 mL) (2)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9764606952667236,
        "detection_dpi": 400
      }
    },
    {
      "id": "c9eb527e",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        198.51998901367188,
        607.1736450195312,
        1636.7210693359375,
        760.4501342773438
      ],
      "text": "Description (11)].\n5\nWARNINGS AND PRECAUTIONS\n5.1 Managing Allergic Reactions\nAppropriate medical treatment must be immediately available to manage potentia",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9550870656967163,
        "detection_dpi": 400
      }
    },
    {
      "id": "ff6488c6",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        1854.202880859375,
        227.31640625,
        3211.706787109375,
        365.5500793457031
      ],
      "text": "data for Flublok are presented fromfour clinical trials (Studies 1, 2, 3, and 4). Data\na placebo-controlled trial in adults 18 through 49 years of age (Study 1) are\nnted, followed by data pooled according to age group fromStudies 2 and 4 (adults\nough 64 years of age) and Studies 3 and 4 (adults aged 65 years and older).",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9474968910217285,
        "detection_dpi": 400
      }
    },
    {
      "id": "173ee6b9",
      "page_index": 0,
      "role": "Title",
      "bbox": [
        2294.685546875,
        427.83001708984375,
        2704.42919921875,
        480.001220703125
      ],
      "text": "y\nhrough 64 years of age, a\ni\nd\nl\nb\nti",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9620814919471741,
        "detection_dpi": 400
      }
    },
    {
      "id": "6d4433bf",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        233.89590454101562,
        1229.984619140625,
        1537.576904296875,
        1329.5211181640625
      ],
      "text": "g\ndminister Flublok as a single 0.5 mL dose.\n2 Administration",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9357691407203674,
        "detection_dpi": 400
      }
    },
    {
      "id": "6bcf6f69",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        212.63404846191406,
        2787.445556640625,
        1653.518798828125,
        3023.86279296875
      ],
      "text": "FULL PRESCRIBING INFORMATION: CONTENTS*\n1\nINDICATIONS AND USAGE\nDOSAGE AND ADMINISTRATION",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9127504825592041,
        "detection_dpi": 400
      }
    },
    {
      "id": "29632d88",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        185.6055908203125,
        3767.89990234375,
        1633.1356201171875,
        3905.962646484375
      ],
      "text": "Initial U.S. Approval: 2013\n———————————\nINDICATIONS AND USAGE\n———————————\nFlublok is a vaccine indicated for active immunization for the prevention of disease",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9259337782859802,
        "detection_dpi": 400
      }
    },
    {
      "id": "934f4ad4",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        1811.969970703125,
        1213.8316650390625,
        2678.6064453125,
        1274.0797119140625
      ],
      "text": "adults 18 through 49 years of age, the most commo\nction was pain (37%); the most common (≥10%) solic",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9104158282279968,
        "detection_dpi": 400
      }
    },
    {
      "id": "54494a7c",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        212.66310119628906,
        3159.75732421875,
        1666.3052978515625,
        3359.128173828125
      ],
      "text": "————————————\nCONTRAINDICATIONS\n————————————\n• Do not administer Flublok to anyone with a history of severe allergic reactions\n(e.g., anaphylaxis) to any component of the vaccine. (4, 6.2, 11)\n——————————\nWARNINGS AND PRECAUTIONS\n——————————",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8680484294891357,
        "detection_dpi": 400
      }
    },
    {
      "id": "821d9ca6",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        1802.82763671875,
        1037.7015380859375,
        3212.082763671875,
        1181.8193359375
      ],
      "text": "re headache (15%), fatigue (15%) and muscle pain (11%). (6.1)\nadults 50 through 64 years of age, the most common (≥10%) injection site adverse\nction was pain (32%); the most common (≥10%) solicited systemic adverse reactions\nre headache (17%), fatigue (13%), and muscle pain (11%). (6.1)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8766862154006958,
        "detection_dpi": 400
      }
    },
    {
      "id": "b0b52b16",
      "page_index": 0,
      "role": "Title",
      "bbox": [
        210.70233154296875,
        2681.830322265625,
        823.8826293945312,
        2779.52734375
      ],
      "text": "2\nDOSAGE AND ADMINISTRA\n2.1\nDosage",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.7290406227111816,
        "detection_dpi": 400
      }
    },
    {
      "id": "0a38d496",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        233.30503845214844,
        3422.646728515625,
        988.909423828125,
        3541.2333984375
      ],
      "text": "or intramuscular use (0.5 mL). (2)\n—————————\nDOSAGE FORMS AND\nublok is an injection a single dose is 05mL",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.7238772511482239,
        "detection_dpi": 400
      }
    },
    {
      "id": "fa0a7c8d",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        202.96615600585938,
        264.34637451171875,
        1578.935302734375,
        506.8548889160156
      ],
      "text": "5.2 Guillain Barré Syndrome\nIf GBS has occurred within 6 weeks of receipt of a prior inﬂuenza vaccine, the deci\ntogiveFlublokshouldbebasedoncareful considerationof thepotential beneﬁtsandr\nThe 1976 swine inﬂuenza vaccine was associated with an increased frequenc\nGuillain-BarréSyndrome(GBS). Evidenceforacausal relationof GBSwithotherinﬂue\nvaccines is inconclusive; if an excess risk exists, it is probably slightly more than",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.6386746168136597,
        "detection_dpi": 400
      }
    },
    {
      "id": "afb62b8f",
      "page_index": 0,
      "role": "Text",
      "bbox": [
        2901.12158203125,
        1278.989990234375,
        3197.507080078125,
        1332.195556640625
      ],
      "text": "ection-site adverse",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.5022375583648682,
        "detection_dpi": 400
      }
    },
    {
      "id": "83a3c2c9",
      "page_index": 1,
      "role": "List",
      "bbox": [
        195.29986572265625,
        247.847900390625,
        1662.626708984375,
        1675.388427734375
      ],
      "text": "Nausea\n6\n1\n<1\n5\n1\n<1\nJoint pain\n4\n<1\n<1\n4\n<1\n<1\nChills\n3\n<1\n<1\n3\n<1\n<1\nFever¶\n<1\n<1\n<1\n<1\n<1\n<1\nNOTE: Data based on the most severe response reported by subjects. Results ≥1%\nreported to nearest whole percent; results >0 but <1% reported as <1%.\n*Total VaccinatedCohort isdeﬁnedasall randomizedsubjectswhoreceivedstudyvaccine\naccording to the treatment actually received and who provided data.\n†Study 1 is registered as NCT00539981 under the National Clinical Trials registry.\n‡Denominators for Study 1: The total number of enrolled, randomized, and vaccinated\nsubjectswas2344intheFlublokgroupand2304intheplacebogroup. For all categories\nexcept fever, the number of subjects with missing values was 72 in the Flublok group\nand73inthePlacebogroupsothat thesedenominatorsare2272and2231respectively.\nFor fever, 89 Flublok recipients and 104 Placebo recipients were missing data, making\nthese denominators 2255 and 2200 respectively.\n§Moderate=hadit, andit was badenoughtoprevent asigniﬁcant part of usual activities;\nSevere = had it, and it prevented most or all of normal activities, or had to see a doctor\nfor prescription medicine.\n¶Fever deﬁned as ≥100.4°F (38°C). Mild (≥100.4° to <101.1°F); Moderate (≥101.2°F to\n<102.2°F); Severe (≥102.2°F)\nAcross three clinical trials (Studies 2 – 4, Tables 2 and 3) a total of 2050 adults age 50\nyears and older received Flublok and 2048 received a U.S.-licensed trivalent inactivated\ninﬂuenza vaccine (IIV3) comparator. The mean age of Flublok study participants was 65\nyears; 56% were female and 80% were Caucasian.\nThe incidence of solicited reactogenicity differed between adults 50 through 64 years of\nage and adults aged 65 years and older. Therefore, data from Studies 2, 3, and 4 were\npooled according to age group and are presented separately (Tables 2 and 3).\nM t d\nti\ni b th\nild i\nit",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9599708318710327,
        "detection_dpi": 400
      }
    },
    {
      "id": "ebefaa7e",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        208.1534423828125,
        3027.46044921875,
        1657.384765625,
        3672.483642578125
      ],
      "text": "endpoint.\nStudy 1 (NCT00539981) included 4648 subjects 18 through 49 years of age for safety\nanalysis, randomized to receive Flublok (n=2344) or placebo (n=2304) (1) (see Clinical\nStudies [14.1]).\nStudy 2 (NCT00539864) included 602 subjects 50 through 64 years of age for safety\nanalysis, randomized to receive Flublok (n=300) or another U.S.-licensed trivalent\ninﬂuenza vaccine (Fluzone, manufactured by SanoﬁPasteur, Inc.) as an active control\n(n=302) (2).\nStudy 3 (NCT00395174) included 869 subjects aged 65 years and older for safety\nanalysis, randomized to receive Flublok (n=436) or another U.S.-licensed trivalent\ninﬂuenza vaccine (Fluzone) as an active control (n=433) (3).\nStudy 4 (NCT01825200) included 2627 subjects aged 50 years and older for safety\nanalysis, randomized to receive Flublok (n=1314) or another U.S.-licensed trivalent\ninﬂuenzavaccine(Aﬂuria, manufacturedbybioCSLPtyLtd.)asanactivecontrol (n=1313).",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9795379042625427,
        "detection_dpi": 400
      }
    },
    {
      "id": "f34c0cf1",
      "page_index": 1,
      "role": "Table",
      "bbox": [
        235.40121459960938,
        1871.2586669921875,
        1650.41748046875,
        3012.401123046875
      ],
      "text": "[TABLE 3 - See table_p2_f34c0cf1.png]",
      "html": null,
      "image_path": "figures/table_p2_f34c0cf1.png",
      "metadata": {
        "score": 0.8668229579925537,
        "detection_dpi": 400
      }
    },
    {
      "id": "42ffcada",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        253.31182861328125,
        1700.46923828125,
        1613.6163330078125,
        1844.32666015625
      ],
      "text": "Fatigue\n15\n3\n<1\n14\n3\n<1\nMuscle Pain\n11\n2\n<1\n7\n<1\n<1",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9946355223655701,
        "detection_dpi": 400
      }
    },
    {
      "id": "b848c5a1",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        1804.1204833984375,
        2250.630859375,
        3143.461181640625,
        2406.837646484375
      ],
      "text": "r prescription medicine.\never deﬁned as ≥100.4°F (38°C). Mild (≥100.4° to <101.1°F); Moderate (≥101.2°F\n102.2°F); Severe(≥102.2°F) For fever, 12Flublokrecipientsand5IIV3recipientsw\nissing data, making these denominators 964 and 962, respectively.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.986389696598053,
        "detection_dpi": 400
      }
    },
    {
      "id": "d3030a86",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        1767.0870361328125,
        1508.3216552734375,
        3203.6220703125,
        2167.498046875
      ],
      "text": "Table 3: Frequency of Solicited Local Injection Site Adverse Reactions and\nSystemic Adverse Reactions within 7 Days of Administration of Flublok or\nComparator in Adults ≥65 Years of Age, Studies 3 and 4, Total Vaccinated\nCohort *,†\nFlublok\nN=1078\nIIV3†\nN=1081\nAny\nMod‡\nSev‡\nAny\nMod‡\nSev‡\nLocal\n%\nPain\n19\n<1\n<1\n20\n<1\n<1\nRedness\n7\n1\n<1\n7\n1\n1\nFirmness/Swelling\n7\n2\n<1\n7\n<1\n<1",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9044877886772156,
        "detection_dpi": 400
      }
    },
    {
      "id": "98bb0fd7",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        1803.889404296875,
        222.8026580810547,
        3131.3623046875,
        376.50732421875
      ],
      "text": "r prescription medicine.\never deﬁned as ≥100.4°F (38°C). Mild (≥100.4° to <101.1°F); Moderate (≥101.2°\n102.2°F); Severe (≥102.2°F)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9744651317596436,
        "detection_dpi": 400
      }
    },
    {
      "id": "10514216",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        1758.22900390625,
        3538.15673828125,
        3202.03369140625,
        3959.60791015625
      ],
      "text": "Flublok\nN=972\nIIV3†\nN=967\nAny\nMod‡\nSev‡\nAny\nMod‡\nSev‡\nLocal\n%\nPain\n32\n2\n<1\n37\n<1\n0\nFirmness/Swelling\n7\n2\n<1\n6\n1\n<1\nRedness\n6\n2\n<1\n5\n1\n<1",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9077165722846985,
        "detection_dpi": 400
      }
    },
    {
      "id": "edbe0f24",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        237.798828125,
        3739.2978515625,
        1649.846435546875,
        3768.8134765625
      ],
      "text": "ays following receipt of vaccine. Study 4 also actively solicited pre speciﬁed common\niti it t\nti\nth\nh 30 d\nf ll\ni\ni t f\ni\ni",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9301831126213074,
        "detection_dpi": 400
      }
    },
    {
      "id": "453fdd41",
      "page_index": 1,
      "role": "Table",
      "bbox": [
        1761.321044921875,
        2443.716064453125,
        3209.23046875,
        3537.64306640625
      ],
      "text": "[TABLE 12 - See table_p2_453fdd41.png]",
      "html": null,
      "image_path": "figures/table_p2_453fdd41.png",
      "metadata": {
        "score": 0.7490091323852539,
        "detection_dpi": 400
      }
    },
    {
      "id": "ec162437",
      "page_index": 1,
      "role": "Table",
      "bbox": [
        1783.9140625,
        408.8244323730469,
        3197.75244140625,
        1493.614501953125
      ],
      "text": "[TABLE 9 - See table_p2_ec162437.png]",
      "html": null,
      "image_path": "figures/table_p2_ec162437.png",
      "metadata": {
        "score": 0.7238216996192932,
        "detection_dpi": 400
      }
    },
    {
      "id": "734d58e8",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        204.3505859375,
        4021.258056640625,
        1648.011962890625,
        4185.06201171875
      ],
      "text": "Reactogenicity data froma small Phase 2 trial (Study 5) in adults 18 through 49 years of\nage, 153 of whom received Flublok 135mcg, are not presented. However, subjects from\nStudy 5 are included in the description of deaths and serious adverse events (SAEs). In\nall st dies local (injectionsite) ands stemic ad ersereactions eresolicited iththe se",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8317047953605652,
        "detection_dpi": 400
      }
    },
    {
      "id": "e5dcd882",
      "page_index": 1,
      "role": "Text",
      "bbox": [
        217.34739685058594,
        3820.575927734375,
        1647.6580810546875,
        3977.443359375
      ],
      "text": "of a memory aid for 7 days following vaccination, and unsolicited adverse reactions were\ncollected for 28-30 days post-vaccination. In Studies 1- 3 and 5, SAEs were collected for\n6 months post-vaccination via clinic visit or telephone follow up on Day 28, telephone\nollow up on Day 180 or by spontaneous reporting Study 4 collected SAEs through 30",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.7915949821472168,
        "detection_dpi": 400
      }
    },
    {
      "id": "f2682876",
      "page_index": 2,
      "role": "List",
      "bbox": [
        190.64813232421875,
        322.5360107421875,
        1684.283447265625,
        2792.874267578125
      ],
      "text": "y\ng\n,\nq\ny\np\n(Flublok 1.3%, IIV3 0.8%) over the 30 day follow-up period.\nFlublok Quadrivalent\nFlublokQuadrivalent hasbeenadministeredtoandsafetydatacollectedfrom4328adults\n50 years of age and older (Study 61) and 998 adults 18-49 years of age (Study 72).\nSAEs were collected for 6 months post-vaccination via clinic visit or remote contact.\nStudy 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to\nreceive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by\nGlaxoSmithKline) as an active control [see Clinical Studies (14.1)]. The safety analysis\npopulation included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine\nrecipients. The mean age of participants was 62.7 years. Overall, 58%of subjects were\nfemale, 80% white/Caucasian, 18% black/African American, 0.9% American Indian/\nAlaskan Native, 0.4% Asian, 0.2% Native Hawaiian/Paciﬁc Islander, 0.7% other racial\ngroups, and 5% of Hispanic/Latino ethnicity.\nAmongadults50yearsof ageandolder (Study6), therewerenoSAEsconsideredrelated\nto study vaccine.\nStudy 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to\nreceive Flublok Quadrivalent or a Comparator inactivated inﬂuenza vaccine (Fluarix®\nQuadrivalent, manufacturedby GlaxoSmithKline). Thesafety analysis populationincluded\n998recipients of Flublok Quadrivalent and332Comparator vaccinerecipients. Themean\nage of participants was 33.5 years. Overall, 65% of subjects were female, 59%\nwhite/Caucasian, 37% black/African American, 1.0% Native Hawaiian/Paciﬁc Islander,\n0.8%American Indian/Alaskan Native, 0.5%Asian, 1.4%other racial groups, and 16%of\nHispanic/Latino ethnicity.\nAmongadults18-49yearsof age(Study7), through6monthspost-vaccination, therewere\nno SAEs considered related to study vaccine.\n1NCT02285998\n2NCT02290509\n6.2 Postmarketing Experience\nThe following events have been spontaneously reported during post approval use of\nFlublok or Flublok Quadrivalent. They aredescribedbecauseof thetemporal relationship,\nthe biologic plausibility for a causal relationship to Flublok or Flublok Quadrivalent, and\ntheir potential seriousness. Because these events are reported voluntarily from a\npopulation of uncertain size, it is not always possible to reliably estimate their frequency\nor establish a causal relationship to vaccine exposure.\nImmune system disorders: anaphylaxis, allergic reactions, and other forms of hypersen-\nsitivity (including urticaria).\nNervous system disorders: facial palsy (Bell’s palsy), Guillain-Barré syndrome, syncope.\n8\nUSE IN SPECIFIC POPULATIONS\n8.1 Pregnancy\nPregnancy Exposure\nThere is a pregnancy exposure registry that monitors pregnancy outcomes in women\nexposed to Flublok.\nHealthcare providers are encouraged to enroll women who receive Flublok during\npregnancy in SanoﬁPasteur Inc.’s vaccination pregnancy registry by calling 1-800-822-\n2463.\nRisk Summary\nAll pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S.\ngeneral population, theestimatedbackgroundrisks of major birthdefects andmiscarriage\ninclinicallyrecognizedpregnanciesare2%to4%and15%to20%, respectively.Available\ndataonFlublokandFlublokQuadrivalent administeredtopregnant womenarelimitedand\ninsufficient to inform vaccine-associated risks in pregnant women.\nA developmental study of Flublok has been performed in rats administered 05 mL",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8227132558822632,
        "detection_dpi": 400
      }
    },
    {
      "id": "08b571b6",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1754.544677734375,
        3686.943603515625,
        3205.92431640625,
        4183.00927734375
      ],
      "text": "Clinical Considerations\nDisease-associated Maternal and/or Embryo/Fetal Risk\nPregnant womenareat increasedriskof complicationsassociatedwithinﬂuenzainfection\ncompared to non-pregnant women. Pregnant women with inﬂuenza may be at increased\nrisk for adverse pregnancy outcomes, including preterm labor and delivery.\nData\nAnimal\nIn a developmental toxicity study, female rats were administered Flublok by intramuscular\ninjectiontwiceprior tomating(35days and14days prior tomating) andongestationDay\n6. The total dose was 0.5 mL (divided) on each occasion (a human dose is 0.5 mL). No\nvaccine-related fetal malformations or variations and no adverse effects on pre-weaning",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.984696626663208,
        "detection_dpi": 400
      }
    },
    {
      "id": "d5e82df5",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        203.134521484375,
        2973.12841796875,
        1672.9398193359375,
        3351.893310546875
      ],
      "text": "occurring in 1%-2% of subjects, were nasopharyngitis, upper respiratory infection,\nheadache, cough, nasal congestion, pharyngolaryngeal pain, and rhinorrhea.\nAmong adults 50-64 years of age (Studies 2 and 4 pooled), the most frequent unsolicited\nadverseevents, occurringin1%of subjects, werediarrheaandcough.Amongadults≥65\nyears of age (Studies 3 and 4 pooled), the most frequent unsolicited adverse events,\noccurring in 1% of subjects, were nasopharyngitis and cough.\nAmong adults 50 years of age and older (Study 4) for whom the incidence of rash,\nurticaria, swelling, non- pitting edema, or other potential hypersensitivity reactions were",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9843689203262329,
        "detection_dpi": 400
      }
    },
    {
      "id": "f3d0850d",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1752.22900390625,
        1150.3892822265625,
        3198.83203125,
        1427.096435546875
      ],
      "text": "( )\ny)\nAntibodies against one inﬂuenza virus type or subtype confer limited or no protection\nagainst another. Furthermore, antibodies to one antigenic variant of inﬂuenza virus might\nnot protect against a new antigenic variant of the same type or subtype. Frequent\ndevelopment of antigenicvariantsthroughantigenicdrift isthevirologicbasisfor seasonal\nepidemicsandthereasonfor theusual replacement of oneor moreinﬂuenzavirusstrains\nin each year’s inﬂuenza vaccine.\nG",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9848549962043762,
        "detection_dpi": 400
      }
    },
    {
      "id": "c8f77238",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1757.90576171875,
        1456.8125,
        3198.711669921875,
        1706.224365234375
      ],
      "text": "syringes contain no natural rubber latex.\n12\nCLINICAL PHARMACOLOGY\n12.1 Mechanism of Action\nFlublok contains recombinant HAproteins of the three strains of inﬂuenza virus speciﬁed\nby health authorities for inclusion in the annual seasonal vaccine. These proteins function\nas antigens which induce a humoral immune response, measured by hemagglutination\nhibiti\n(HI)\ntib d )",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9876569509506226,
        "detection_dpi": 400
      }
    },
    {
      "id": "369e43bd",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1752.9776611328125,
        1726.7962646484375,
        3191.553955078125,
        2159.215087890625
      ],
      "text": "requirements. For the2024-2025inﬂuenzaseasonit is formulatedtocontain135mcgHA\nper 0.5mLdose, with45mcgHAof eachof thefollowing3inﬂuenzavirusstrains:A/West\nVirginia/30/2022 (A/Wisconsin/67/2022 pdm09-like virus) (H1N1), A/Massachusetts/18/\n2022 (H3N2) and B/Austria/1359417/2021.\nA single 0.5 mL dose of Flublok contains sodium chloride (4.4 mg), monobasic sodium\nphosphate (0.2 mg), dibasic sodiumphosphate (0.5 mg), and polysorbate 20 (Tween®20)\n(27.5mcg). Each0.5mLdoseof Flublokmayalsocontainresidual amountsof baculovirus\nandSpodopterafrugiperdacell proteins (≤14.3mcg), baculovirus andcellular DNA(≤10\nng), and Triton X-100 (≤100 mcg).\nFlublok contains no egg proteins, antibiotics, or preservatives. The single-dose, preﬁlled\ni\nt i\nt\nl\nbb\nl t",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9511477947235107,
        "detection_dpi": 400
      }
    },
    {
      "id": "c4021687",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1771.05126953125,
        2178.278076171875,
        3202.707763671875,
        2366.78369140625
      ],
      "text": "xpressed in this cell line using a baculovirus vector (Autographa californica nuclear\nolyhedrosis virus), extracted from the cells with Triton X-100 and further puriﬁed by\nolumn chromatography. The puriﬁed HAs are then blended and ﬁlled into single-dose\nyringes.\nFlublok is standardized according to United States Public Health Service (USPHS)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9852125644683838,
        "detection_dpi": 400
      }
    },
    {
      "id": "a16c4598",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1755.70556640625,
        847.6258544921875,
        3193.952880859375,
        1136.07666015625
      ],
      "text": "13\nNONCLINICAL TOXICOLOGY\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\nFlublok has not been evaluated for carcinogenic or mutagenic potential, or for impairment\nof male fertility in animals.\n14\nCLINICAL STUDIES\n14.1 Efficacy Against Laboratory-Conﬁrmed Inﬂuenza\nThe efficacy of Flublok in protecting against culture-conﬁrmed inﬂuenza illness was",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9570881724357605,
        "detection_dpi": 400
      }
    },
    {
      "id": "655b1bb5",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1770.9136962890625,
        2977.242431640625,
        3196.196533203125,
        3220.943359375
      ],
      "text": "Data froma randomized, controlled trial demonstrated that children 6 months to less than\nyears of age had diminished hemagglutinin inhibition (HI) responses to Flublok\nomparedtoaU.S.-licensedinﬂuenzavaccineapprovedforuseinthispopulation, strongly\nuggestingthat Flublok wouldnot beeffectiveinchildrenyounger than3years of age(6).\nSafety and effectiveness of Flublok have not been established in children 3 years to less\nhan 18 years of age.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9625499248504639,
        "detection_dpi": 400
      }
    },
    {
      "id": "8c5b8ea1",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1747.3577880859375,
        2799.327880859375,
        3197.551025390625,
        2975.85107421875
      ],
      "text": "8.5 Geriatric Use\nData froman efficacy study (Study 6), which included 1759 subjects ≥65 years and 525\nsubjects ≥75 years who received Flublok Quadrivalent, are insufficient to determine\nwhether elderly subjects respond differently from younger subjects (See Clinical Studies",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9690775871276855,
        "detection_dpi": 400
      }
    },
    {
      "id": "190b3427",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        225.14344787597656,
        3824.33984375,
        1642.3656005859375,
        4039.6533203125
      ],
      "text": "p\ny\ng\neither was consideredvaccine-related. SAEs werereportedby 32Flublok recipients and\n5 placebo recipients. One SAE in a Flublok recipient was assessed as possibly related\no the vaccine: pleuropericarditis with effusions requiring hospitalization and drainage. No\npeciﬁc cause was identiﬁed. The patient recovered.\nAmong adults 50 64 years of age (Studies 2 and 4 pooled) through up to 6 months or",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9577653408050537,
        "detection_dpi": 400
      }
    },
    {
      "id": "5723e20e",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1757.6212158203125,
        525.8806762695312,
        3188.84912109375,
        761.651611328125
      ],
      "text": "n the U.S. during the 2007 2008 inﬂuenza season in adults 18 49 years of age (Study\n1). (1)\nStudy 1 enrolled and vaccinated 4648 healthy adults (mean age 32.5 years) randomized\nn a 1:1 ratio to receive a single dose of Flublok (n=2344) or saline placebo (n=2304)\nAmong enrolled subjects, 59%were female, 67%were white, 19%African-American, 2%\nAsian, < 1%otherraces, and11%of Latino/Hispanicethnicity. Culture-conﬁrmedinﬂuenza",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9540386199951172,
        "detection_dpi": 400
      }
    },
    {
      "id": "2f9ba47d",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1776.558349609375,
        3523.558837890625,
        3189.8037109375,
        3660.192138671875
      ],
      "text": "evelopment or female fertility were observed in the study.\n.2 Lactation\nisk Summary\nisnot knownwhether Flublokisexcretedinhumanmilk Dataarenot availabletoassess",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9609693288803101,
        "detection_dpi": 400
      }
    },
    {
      "id": "66911863",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        220.67938232421875,
        3357.218017578125,
        1630.0023193359375,
        3468.820068359375
      ],
      "text": "p\nj\n,\np\n,\np\nonsidered related to the study vaccines.\nn Study 1 (adults 18-49 years of age), the most frequent unsolicited adverse events\ni\ni\n1%2%\nf\nbj\nh\ni i\ni\ni f\ni",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9374784827232361,
        "detection_dpi": 400
      }
    },
    {
      "id": "bbb60705",
      "page_index": 2,
      "role": "Title",
      "bbox": [
        214.4805450439453,
        2823.98388671875,
        455.3550720214844,
        2875.8779296875
      ],
      "text": "1.9%and 0.9%\n7d\nf ll\ni",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9333536028862,
        "detection_dpi": 400
      }
    },
    {
      "id": "2842ed8d",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1735.9564208984375,
        283.186767578125,
        3193.837158203125,
        493.3288879394531
      ],
      "text": "was assessed by active and passive surveillance for inﬂuenza like illness (ILI) beginning\n2 weeks post-vaccination until the end of the inﬂuenza season, approximately 7 months\npost- vaccination. ILI was deﬁned as having at least 2 of 3 symptoms (no speciﬁed\nduration) in the following categories: 1) fever ≥100°F; 2) respiratory symptoms (cough,\nsore throat, or runny nose/stuffy nose); or 3) systemic symptoms (myalgias, arthralgias,\nheadache chills/sweats or tiredness/malaise) For subjects with an episode of ILI nasal",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8943033814430237,
        "detection_dpi": 400
      }
    },
    {
      "id": "cc84baab",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1765.5736083984375,
        2401.22802734375,
        3194.32421875,
        2622.872314453125
      ],
      "text": "[\n]\nj\ng\nhemagglutinin(HA) proteinsfromthreeinﬂuenzavirusesfor intramuscular use. It contains\npuriﬁedHAproteins producedinacontinuous insect cell line(expresSF+®) that is derived\nrom Sf9 cells of the fall armyworm, Spodoptera frugiperda (which is related to moths,\ncaterpillars and butterﬂies), and grown in serum-free medium composed of chemically-\ndeﬁned lipids, vitamins, amino acids, and mineral salts. Each of the three HAs is",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8727145195007324,
        "detection_dpi": 400
      }
    },
    {
      "id": "52e67144",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        230.41424560546875,
        4058.09912109375,
        1645.186279296875,
        4194.560546875
      ],
      "text": "mong adults 18-49 years of age (Studies 1 and 5 pooled), through 6 months\nost-vaccination, two deaths were reported, one in a Flublok recipient and one in a\nacebo recipient Both deaths occurred more than 28 days following vaccination and",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8542278409004211,
        "detection_dpi": 400
      }
    },
    {
      "id": "a8804396",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1770.897705078125,
        2634.852294921875,
        3155.0810546875,
        2747.1826171875
      ],
      "text": "manufactured using the same process and have overlapping compositions.\n1\nDESCRIPTION\nFlublok [Inﬂuenza Vaccine] is a sterile, clear, colorless injection containing recombina",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.7603784799575806,
        "detection_dpi": 400
      }
    },
    {
      "id": "fde8870a",
      "page_index": 2,
      "role": "Title",
      "bbox": [
        210.58509826660156,
        2888.583740234375,
        458.5666198730469,
        2940.79736328125
      ],
      "text": "activelysolicited\n1.6%of IIV3 rec",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.754931628704071,
        "detection_dpi": 400
      }
    },
    {
      "id": "e939a1dd",
      "page_index": 2,
      "role": "Title",
      "bbox": [
        1750.21044921875,
        3461.693115234375,
        2713.41650390625,
        3512.6171875
      ],
      "text": "the effects of Flublok on the breastfed infant or on milk pr",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.7106451392173767,
        "detection_dpi": 400
      }
    },
    {
      "id": "5a6ac378",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        198.80831909179688,
        3642.53466796875,
        1646.1424560546875,
        3745.325927734375
      ],
      "text": "subjects, 6 Flublok recipients and 4 IIV3 recipients. One of the SAEs, vasovagal syncope\nfollowing injection of Flublok, was considered related to administration of study vaccine.\nA\nd lt 65\nf\nd ld\n(St di\n3\nd4\nl d) th\nh\nt 6\nth",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.6959642767906189,
        "detection_dpi": 400
      }
    },
    {
      "id": "84a7858a",
      "page_index": 2,
      "role": "Text",
      "bbox": [
        1723.3701171875,
        3301.471923828125,
        3167.885498046875,
        3452.82568359375
      ],
      "text": "The developmental and health beneﬁts of breastfeeding should be considered along wit\nthe mother’s clinical need for Flublok and any potential adverse effects on the breastfe\nchild fromFlublok or fromthe underlying maternal condition. For preventive vaccines, th\nunderlying condition is susceptibility to disease prevented by the vaccine",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.5864219665527344,
        "detection_dpi": 400
      }
    },
    {
      "id": "85bbc7fb",
      "page_index": 2,
      "role": "Title",
      "bbox": [
        1749.4853515625,
        226.68228149414062,
        2130.921142578125,
        273.3851318359375
      ],
      "text": "headache, chills/sweats\nand throat swab sampl",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.5715404748916626,
        "detection_dpi": 400
      }
    },
    {
      "id": "80e9c90c",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        220.26661682128906,
        3307.235595703125,
        1640.7451171875,
        3872.00341796875
      ],
      "text": "6 8)\nThe pre-deﬁned success criterion for the primary efficacy analysis was that the lowe\nbound of the 95%conﬁdence interval (CI) of VEshould be at least 40%. Vaccine efficacy\nagainst antigenically matched culture-conﬁrmed CDC-ILI could not be determined reliably\nbecause 96% of the inﬂuenza isolates obtained from subjects in Study 1 were not\nantigenically matched to the strains represented in the vaccine. An exploratory analysis\nof VE of Flublok against all strains, regardless of antigenic match, isolated from any\nubject with an ILI, not necessarily meeting CDC- ILI criteria, demonstrated an efficacy\nestimate of 44.8% (95% CI 24.4, 60.0). See Table 4 for a presentation of VE by case\ndeﬁnition and antigenic similarity.\nTable 4: Vaccine Efficacy Against Culture-Conﬁrmed Inﬂuenza in Healthy\nAdults 18-49 Years of Age, Study 1*",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9909710884094238,
        "detection_dpi": 400
      }
    },
    {
      "id": "48e23826",
      "page_index": 3,
      "role": "Figure",
      "bbox": [
        1777.2728271484375,
        532.2280883789062,
        3158.498046875,
        1349.822265625
      ],
      "text": "[FIGURE 11 - See figure_p4_48e23826.png]",
      "html": null,
      "image_path": "figures/figure_p4_48e23826.png",
      "metadata": {
        "score": 0.9512621164321899,
        "detection_dpi": 400
      }
    },
    {
      "id": "f794ce2d",
      "page_index": 3,
      "role": "List",
      "bbox": [
        1757.5234375,
        2305.309326171875,
        3206.330810546875,
        3441.7197265625
      ],
      "text": "Inﬂuenza\n96\n2.2\n138\n3.2\n0.70\n30 (10, 47)\nAll rtPCR-positive\nInﬂuenza A§\n73\n1.7\n114\n2.7\n0.64\n36 (14, 53)\nAll rtPCR-positive\nInﬂuenza B§\n23\n0.5\n24\n0.6\n0.96\n4 (-72, 46)\nAll Culture-conﬁrmed\nProtocol- deﬁned ILI§,¶\n58\n1.3\n101\n2.3\n0.57\n43 (21, 59)\nAbbreviations: rtPCR=reversetranscriptasepolymerasechainreaction; Comparator=U.S.-\nicensedquadrivalent inactivatedinﬂuenzavaccine, FluarixQuadrivalent, manufacturedby\nGlaxoSmithKline; n=number of inﬂuenzacases; N=number of subjectsintreatment group;\nRR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) × 100].\n*Study 6 is registered as NCT02285998.\n†Efficacy Population included all randomized subjects who received study vaccine and\nprovidedanyfollow-updocumentationfor inﬂuenza-likeillnessbeginningat least 14days\npost-vaccination. Excluded subjects with protocol deviations that could adversely affect\nefficacy.\n‡Primary Analysis. All cases of rtPCR-conﬁrmed inﬂuenza are included. Antigenic char-\nacterizationandgeneticsequencingtodeterminesimilarityof isolatestovaccineantigens\nwere not performed. CDC surveillance data indicated that the majority of inﬂuenza\nA/H3N2 wild type viruses were antigenically distinct whereas inﬂuenzaA/H1N1 and type\nB viruses were antigenically similar to vaccine antigens during the 2014-2015 season.\nStudy 6 met the pre-speciﬁed success criterion for the primary endpoint (lower limit of\nthe 2-sided 95% CI of vaccine efficacy for Flublok Quadrivalent relative to Comparator\nshould be not less than - 20%)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8916413187980652,
        "detection_dpi": 400
      }
    },
    {
      "id": "c8f6b3e5",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        211.62083435058594,
        532.7598266601562,
        1636.5172119140625,
        911.2854614257812
      ],
      "text": "reaction(rtPCR) -conﬁrmedinﬂuenzawasassessedbyactiveandpassivesurveillancefo\nnﬂuenza-likeillness(ILI)beginning2weekspost-vaccinationuntil theendof theinﬂuenza\nseason, approximately 6months post- vaccination. ILI was deﬁnedas havingat least one\nsymptom (no speciﬁed duration) in each of two categories of respiratory and systemic\nsymptoms. Respiratory symptoms included sore throat, cough, sputum production\nwheezinganddifficultybreathing. Systemicsymptomsincludedfever > 99°F(>37°C) oral\nchills, fatigue, headache and myalgia. For subjects with an episode of ILI, a nasopha\nryngeal swab sample was collected for rtPCR testing and reﬂex viral culture of rtPCR\npositive samples.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9828259348869324,
        "detection_dpi": 400
      }
    },
    {
      "id": "06f9ea9f",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        215.37582397460938,
        3879.559814453125,
        1654.01220703125,
        4181.205078125
      ],
      "text": "The primary efficacy endpoint of Study 1 was Centers for Disease Control-deﬁned\nnﬂuenza-like illness (CDC-ILI) with a positive culture for an inﬂuenza virus strain\nantigenically resembling a strain represented in Flublok. CDC-ILI is deﬁned as fever of\n≥100°F oral accompanied by cough, sore throat, or both on the same day or on\nconsecutive days. Attack rates and vaccine efficacy (VE), deﬁned as the reduction in the\nnﬂuenzarateforFlublokrelativetoplacebo,werecalculatedforthetotal vaccinatedcohort\nn=4648)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9898788928985596,
        "detection_dpi": 400
      }
    },
    {
      "id": "bf03b169",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        245.8236846923828,
        3065.512939453125,
        1630.4306640625,
        3298.099609375
      ],
      "text": "Case deﬁnition\nFlublok\n(N=2344)\nSaline\nPlacebo\n(N=2304)\nFlublok\nVaccine\nEfficacy†,\n%\n95%\nConﬁdence\nInterval\nCases,\nn\nRate,\n%\nCases,\nn\nRate,\n%",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9949146509170532,
        "detection_dpi": 400
      }
    },
    {
      "id": "71894222",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        201.1509552001953,
        228.26222229003906,
        1648.0721435546875,
        518.152099609375
      ],
      "text": "The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol-deﬁned ILI due to\nany strain of inﬂuenza. Attack rates and relative vaccine efficacy (rVE), deﬁned as 1 –\n[Attack rate Flublok Quadrivalent/ Attack Rate Comparator], were calculated for the total\nefficacy population (n=8604) for the primary efficacy endpoint and for several alternative\nefficacy endpoints (Table 5). Antigenic and phylogenetic evaluations of the similarity\n(″matching″) of clinical isolates to vaccine antigens were not performed. CDC epidemio-\nlogical data for the 2014-2015 inﬂuenza season indicated that InﬂuenzaA(H3N2) viruses",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9836641550064087,
        "detection_dpi": 400
      }
    },
    {
      "id": "605a1f9e",
      "page_index": 3,
      "role": "List",
      "bbox": [
        1756.130859375,
        1357.58447265625,
        3206.95703125,
        2251.119873046875
      ],
      "text": "§\ny\ndistinguished by lineage.\n¶Culture of rtPCR-positive samples was performed in MDCK cells.\n15\nREFERENCES\n1. Treanor JJ, El Sahly HM, King J, et. al. Protective efficacy of a trivalent recombinant\nhemagglutininproteinvaccine(FluBlok) against inﬂuenzainhealthyadults: arandomized,\nplacebo-controlled trial. Vaccine. 2011, Vol. 29, pp. 7733-7739.\n2. Baxter R, Patriarca PA, Ensor K, et al. Evaluation of the safety, reactogenicity and\nmmunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin\nnﬂuenza vaccine administered intramuscularly to healthy adults 50-64 years of age.\nVaccine. 2011, Vol. 29, pp. 2272-2278.\n3. Keitel WA, Treanor JJ, El Sahly HM, et.al. Comparative immunogenicity of recom-\nbinant inﬂuenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIVs) among\npersons ≥65 years old. Vaccine. 2009, Vol. 28, pp. 379-385.\n4. Izikson R, Leffell DJ, Bock SA, et. al. Randomized comparison of the safety of\nFlublok®versus licensed inactivated inﬂuenza vaccine in healthy, medically stable adults\n≥50years of age. Vaccine. 2015, Vol. 33, pp. 6622–6628.\n5. TreanorJJ, Schiff GM, HaydenFG, et.al. Safetyandimmunogenicityof abaculovirus-\nexpressed hemagglutinin inﬂuenza vaccine: a randomized controlled trial. JAMA. 2007,\nVol. 297, pp. 1577-1582.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8679383993148804,
        "detection_dpi": 400
      }
    },
    {
      "id": "319d2bf4",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        1790.24267578125,
        352.18310546875,
        3148.6962890625,
        520.67138671875
      ],
      "text": "• Store refrigerated between 2° and 8°C (36° and 46°F).\n• Do not freeze. Discard if product has been frozen.\n• Protect syringes from light.\n• Do not use after expiration date shown on the label.",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9790263175964355,
        "detection_dpi": 400
      }
    },
    {
      "id": "84684524",
      "page_index": 3,
      "role": "Table",
      "bbox": [
        1754.2188720703125,
        3541.367431640625,
        3208.40673828125,
        4157.025390625
      ],
      "text": "[TABLE 14 - See table_p4_84684524.png]",
      "html": null,
      "image_path": "figures/table_p4_84684524.png",
      "metadata": {
        "score": 0.8905076384544373,
        "detection_dpi": 400
      }
    },
    {
      "id": "0bf416fd",
      "page_index": 3,
      "role": "Figure",
      "bbox": [
        209.9026336669922,
        1046.6240234375,
        1655.826416015625,
        2287.572021484375
      ],
      "text": "[FIGURE 3 - See figure_p4_0bf416fd.png]",
      "html": null,
      "image_path": "figures/figure_p4_0bf416fd.png",
      "metadata": {
        "score": 0.7831475138664246,
        "detection_dpi": 400
      }
    },
    {
      "id": "2ced1539",
      "page_index": 3,
      "role": "List",
      "bbox": [
        218.03811645507812,
        2298.145263671875,
        1650.9071044921875,
        2866.444580078125
      ],
      "text": "atc ed st a s\n995)\nAny ILI, all\nmatched strains¶,#\n2\n0.1\n6\n0.3\n67.2\n(-83.2,\n96.8)\nPositive culture with any strain, regardless of match to the vaccine\nCDC-ILI, all\nstrains‡,Þ\n44\n1.9\n78\n3.4\n44.6\n(18.8, 62.6)\nSub-Type A\n26\n1.1\n56\n2.4\n54.4\n(26.1, 72.5)\nType B\n18\n0.8\n23\n1.0\n23.1\n(-49.0,\n60.9)\nAny ILI all strains¶\n64\n27\n114\n49\n448\n(244 600)",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8873748183250427,
        "detection_dpi": 400
      }
    },
    {
      "id": "40063e3c",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        1752.23095703125,
        225.2614288330078,
        3177.88818359375,
        317.80120849609375
      ],
      "text": "17\nPATIENT COUNSELING INFORMATION\nInformthe vaccine recipient of the potential beneﬁts and risks of vaccination with Flublok\nInform the vaccine recipient that:",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9038958549499512,
        "detection_dpi": 400
      }
    },
    {
      "id": "ec2f3422",
      "page_index": 3,
      "role": "Text",
      "bbox": [
        216.48275756835938,
        2933.233642578125,
        1640.6094970703125,
        3046.421630859375
      ],
      "text": "Positive culture with a strain represented in the vaccine\nCDCILI all\n1\n004\n4\n02\n754\n( 1480",
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8946447372436523,
        "detection_dpi": 400
      }
    },
    {
      "id": "460b941c",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        190.7911834716797,
        915.260498046875,
        1590.122802734375,
        968.5117797851562
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.9658605456352234,
        "detection_dpi": 400
      }
    },
    {
      "id": "77f403b1",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        199.48146057128906,
        1116.9986572265625,
        1299.249755859375,
        1166.146728515625
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.950566291809082,
        "detection_dpi": 400
      }
    },
    {
      "id": "d930328a",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        205.33331298828125,
        421.56866455078125,
        1663.1202392578125,
        716.170654296875
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8610508441925049,
        "detection_dpi": 400
      }
    },
    {
      "id": "41a99b7f",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        222.65321350097656,
        826.711669921875,
        1647.1551513671875,
        864.8682250976562
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.889861524105072,
        "detection_dpi": 400
      }
    },
    {
      "id": "40aeb545",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        231.5110626220703,
        240.56088256835938,
        1647.6871337890625,
        374.3254699707031
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.8236666321754456,
        "detection_dpi": 400
      }
    },
    {
      "id": "63743271",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        201.45176696777344,
        1213.513916015625,
        585.59228515625,
        1266.033935546875
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.7801063060760498,
        "detection_dpi": 400
      }
    },
    {
      "id": "43d9a8d1",
      "page_index": 4,
      "role": "Text",
      "bbox": [
        203.8036346435547,
        1015.7003173828125,
        756.5416259765625,
        1066.624755859375
      ],
      "text": null,
      "html": null,
      "image_path": null,
      "metadata": {
        "score": 0.7521759867668152,
        "detection_dpi": 400
      }
    }
  ],
  "metadata": {
    "detection_dpi": 400,
    "total_pages": 5,
    "merge_settings": {
      "merge_overlapping": true,
      "merge_threshold": 0.3,
      "confidence_weight": 0.7,
      "area_weight": 0.3
    },
    "extraction": {
      "text_blocks": 62,
      "figure_blocks": 7,
      "figures_dir": "/Users/saul/projects/solstice/solstice/data/cache/FlublokPI/extracted/figures"
    }
  },
  "reading_order": [
    [
      "fa0a7c8d",
      "c9eb527e",
      "6d4433bf",
      "772dce4f",
      "b0b52b16",
      "6bcf6f69",
      "54494a7c",
      "0a38d496",
      "cd091c03",
      "29632d88",
      "018f3eb5",
      "ff6488c6",
      "173ee6b9",
      "5944136b",
      "821d9ca6",
      "934f4ad4",
      "afb62b8f",
      "3f54d4c6"
    ],
    [
      "83a3c2c9",
      "42ffcada",
      "f34c0cf1",
      "ebefaa7e",
      "edbe0f24",
      "e5dcd882",
      "734d58e8",
      "98bb0fd7",
      "ec162437",
      "d3030a86",
      "b848c5a1",
      "453fdd41",
      "10514216"
    ],
    [
      "f2682876",
      "bbb60705",
      "fde8870a",
      "d5e82df5",
      "66911863",
      "5a6ac378",
      "190b3427",
      "52e67144",
      "85bbc7fb",
      "2842ed8d",
      "5723e20e",
      "a16c4598",
      "f3d0850d",
      "c8f77238",
      "369e43bd",
      "c4021687",
      "cc84baab",
      "a8804396",
      "8c5b8ea1",
      "655b1bb5",
      "84a7858a",
      "e939a1dd",
      "2f9ba47d",
      "08b571b6"
    ],
    [
      "71894222",
      "c8f6b3e5",
      "0bf416fd",
      "2ced1539",
      "ec2f3422",
      "bf03b169",
      "80e9c90c",
      "06f9ea9f",
      "40063e3c",
      "319d2bf4",
      "48e23826",
      "605a1f9e",
      "f794ce2d",
      "84684524"
    ],
    [
      "40aeb545",
      "d930328a",
      "41a99b7f",
      "460b941c",
      "43d9a8d1",
      "77f403b1",
      "63743271"
    ]
  ]
}